A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

Abstract Background The patient population with stage III non-small-cell lung cancer (NSCLC) is heterogeneous, with varying staging characteristics and diverse treatment options. Despite the potential practice-changing implications of randomized controlled trials evaluating the efficacy of periopera...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, Chia-Hung Chen, Chih-Yen Tu, Te-Chun Hsia, Wen-Chien Cheng, Hung-Jen Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-09-01
coleção:	BMC Cancer
Assuntos:	Adenocarcinoma Chemotherapy Epidermal growth factor receptor (EGFR) Stage III Surgery Tyrosine kinase inhibitor (TKI)
Acesso em linha:	https://doi.org/10.1186/s12885-023-11342-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!